HRGN (Harvard Apparatus Regenerative Technology) DeferredTaxAndRevenue: $0.34 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HRGN Harvard Apparatus Regenerative Technology Inc HRGN
14 GF Score
Price $1.05
! 2 Warning Signs
View Full Analysis

What is Harvard Apparatus Regenerative Technology DeferredTaxAndRevenue?

Harvard Apparatus Regenerative Technology HRGN 14 DeferredTaxAndRevenue is $0.34 Mil as of Mar. 2026. GuruFocus rates HRGN with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Harvard Apparatus Regenerative Technology's current deferred tax and revenue for the quarter that ended in Mar. 2026 was $0.34 Mil.

Harvard Apparatus Regenerative Technology DeferredTaxAndRevenue Related Terms

Harvard Apparatus Regenerative Technology DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Harvard Apparatus Regenerative Technology's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Apparatus Regenerative Technology DeferredTaxAndRevenue Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.25

Harvard Apparatus Regenerative Technology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.15 0.13 0.25 0.34
HRGN
14GF Score
Harvard Apparatus Regenerative Technology Inc HRGN
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.34 Mil mean?
Harvard Apparatus Regenerative Technology (HRGN) has a DeferredTaxAndRevenue of $0.34 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Harvard Apparatus Regenerative Technology.
Is Harvard Apparatus Regenerative Technology's DeferredTaxAndRevenue too high?
Harvard Apparatus Regenerative Technology's current DeferredTaxAndRevenue is $0.34 Mil. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's DeferredTaxAndRevenue compare to JVA and BRLS?
Harvard Apparatus Regenerative Technology's DeferredTaxAndRevenue of $0.34 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Consumer Packaged Goods company?
A good DeferredTaxAndRevenue depends on the Consumer Packaged Goods industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Harvard Apparatus Regenerative Technology. Harvard Apparatus Regenerative Technology's current DeferredTaxAndRevenue is $0.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Harvard Apparatus Regenerative Technology (HRGN) has a current DeferredTaxAndRevenue of $0.34 Mil. The current DeferredTaxAndRevenue is $0.34 Mil. Harvard Apparatus Regenerative Technology's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current DeferredTaxAndRevenue is $0.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Harvard Apparatus Regenerative Technology Business Description

Address 84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
14GF Score

Get the complete analysis for HRGN

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.05
Price